Triple
T6495541
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Alkermes |
E148148
|
entity |
| Predicate | hasSubsidiary |
P254
|
FINISHED |
| Object | Alkermes Pharma Ireland Limited |
E148148
|
NE FINISHED |
How this triple was built (2 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Alkermes Pharma Ireland Limited | Statement: [Alkermes, hasSubsidiary, Alkermes Pharma Ireland Limited]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Alkermes Pharma Ireland Limited Context triple: [Alkermes, hasSubsidiary, Alkermes Pharma Ireland Limited]
-
A.
Alkermes
chosen
Alkermes is a biopharmaceutical company that develops innovative medicines for central nervous system disorders and other serious chronic diseases.
-
B.
Elan Pharmaceuticals
Elan Pharmaceuticals was a biotechnology company best known for developing therapies for neurological and autoimmune diseases, including the multiple sclerosis drug Tysabri.
-
C.
Biogen
Biogen is a major American biotechnology company known for developing therapies for neurological and neurodegenerative diseases.
-
D.
Vertex Pharmaceuticals
Vertex Pharmaceuticals is a biotechnology company best known for developing transformative therapies for cystic fibrosis and other serious diseases using a precision medicine approach.
-
E.
Lonza
Lonza is a global Swiss-based life sciences company specializing in pharmaceutical, biotech, and nutrition products and services, particularly in contract development and manufacturing.
- F. None of above.
- G. Unsure - the case is ambiguous/there is not enough information to decide.
Provenance (3 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69c009088f3081909cd467b05919de30 |
completed | March 22, 2026, 3:21 p.m. |
| NER | Named-entity recognition | batch_69c06ab958808190bd85e007e925ffc4 |
completed | March 22, 2026, 10:18 p.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69c653c21f948190989da451bc573b4d |
completed | March 27, 2026, 9:54 a.m. |
Created at: March 22, 2026, 4:53 p.m.